The optimal dose of concomitant albumin for the treatment of hepatorenal syndrome type 1 - what is it? by Pappas, S.C, Wong, F, Sanyal, A, Boyer, T, Jamil, K

Get full text

G14 : Systemic inflammatory response syndrome (SIRS) is a major determinant of treatment response to terlipressin for hepatorenal syndrome type 1 (HRS-1) by Wong, F, Pappas, S.C, Boyer, T.D, Sanyal, A.J, Jamil, K

Get full text

P0198 : Percentage change in serum creatinine (SCr) is a sensitive indicator of therapeutic response to terlipressin in hepatorenal syndrome type 1 (HRS-1) by Boyer, T.D, Sanyal, A.J, Pappas, S.C, Wong, F, Jamil, K

Get full text

SAT-045 - The optimal dose of concomitant albumin for the treatment of hepatorenal syndrome type 1 - what is it? by Pappas, S.C., Wong, F., Sanyal, A., Boyer, T., Jamil, K.

Get full text

[6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO P... by Afdhal, N, O'Brien, C, Godofsky, E, Rodriguez-Torres, M, Pappas, S.C, Lawitz, E, Pockros, P, Sulkowski, M, Jacobson, I, Chao, G, Knox, S, Pietropaolo, K, Brown, N.A

Get full text

39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV:... by Afdhal, N., O Brien, C., Godofsky, E., Rodriguez-Torres, M., Pappas, S.C., Pockros, P., Lawitz, E., Bzowej, N., Rustgi, V., Sulkowski, M., Sherman, K., Jacobson, I., Chao, G., Knox, S., Pietropaolo, K., Brown, N.

Get full text

An evaluation demonstrating continued efficacy and improved safety and tolerability in 17 patients switched to PEGASYS® after discontinuation from REBETRON™ for the treatment of ch... by Perrillo, R.P., Rothstein, K.D., Alam, I., Thuluvath, P.J., Palmer, M., Pockros, P.J., Pappas, S.C., Doerschuk, B.S., Cantwell, S.

Get full text

Pegylated (40 KDA) interferon alfa-2a (PEGASYS®) in new combination therapies: a report of a randomized, multicenter efficacy and safety study by Di Bisceglie, A.M., Bernstein, D.E., Rustgi, V.R., Gitlin, N., Jeffers, L.J., Simon, D., Campagna, J., Pappas, S.C.

Get full text

Therapy with PEGASYS® demonstrates similar efficacy and significantly improved tolerability, quality of life and work productivity compared with REBETRON™ in patients with chronic... by Perrillo, R.P., Rothstein, K.D., Imperial, J., Alam, I., Palmer, M., Pockros, P.J., Pappas, S.C., Doerschuk, B.S., Wynohradnyk, L.

Get full text

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution by PFALLER, M. A, ESPINEL-INGROFF, A, LOCKHART, S. R, MARTIN-MAZUELOS, E, MELHEM, M. S. C, OSTROSKY-ZEICHNER, L, PAPPAS, P, PELAEZ, T, PEMAN, J, REX, J, SZESZS, M. W, CANTON, E, CASTANHEIRA, M, CUENCA-ESTRELLA, M, DIEKEMA, D. J, FOTHERGILL, A, FULLER, J, GHANNOUM, M, JONES, R. N

Get full text

Plant transformation by coinoculation with a disarmed Agrobacterium tumefaciens strain and an Escherichia coli strain carrying mobilizable transgenes by Pappas, K.M, Winans, S.C

Get full text